Skip to main content
EJNMMI Research

Table 4 Quantitation of tumor and liver uptake of 86Y-CHX-A"-panitumumab F(ab')2 by PET imaging.

From: In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

   

Time post-injection (h)

Protein dose

Blocked

Organ

24

48

3 μg

No

Tumor

20.31 ± 1.52a

22.59 ± 1.51

  

Liver

12.98 ± 0.95

11.68 ± 0.43

 

Yes

Tumor

11.37 ± 0.58

9.92 ± 0.66

  

Liver

12.34 ± 0.99

12.95 ± 0.88

15 μg

No

Tumor

20.30 ± 1.01

22.98 ± 0.84

  

Liver

13.84 ± 0.5

11.62 ± 1.12

 

Yes

Tumor

11.44 ± 0.69

11.38 ± 0.96

  

Liver

12.60 ± 0.70

10.66 ± 0.57

  1. The values presented are the percentage of injected dose per cubic centimeter. Receptor-mediated uptake of 86Y-CHX-A"-panitumumab F(ab')2 of LS-174T tumor xenografts and normal organs 2 days post-injection of the RIC. Data represent the mean ± SEM from at least three determinations. The specific activity of the 86Y- CHX-A"-panitumumab F(ab')2 was lowered by the addition of 15 μg of panitumumab F(ab')2.
Back to article page